Effects of sacubitril/valsartan on cardiac remodeling in heart failure with reduced ejection fraction: An integrated study of molecular biomarkers and imaging techniques
Open Access
- 30 January 2025
- journal article
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 183, 117874
Abstract
No abstract availableKeywords
Funding Information
- European Commission (PI-0131/2020)
- University of Malaga
- Regional Government of Andalusia Ministry of Health and Consumer Affairs (RH-0095-2020, PI-0131/2020)
- Carlos III Health Institute (CM23/00125, PI23/00293)
- Government of Andalusia Ministry of Economic Transformation Industry Knowledge and Universities (ProyExcel_01009)
- Consejería de Economía, Conocimiento, Empresas y Universidad, Junta de Andalucía
- European Social Fund Plus (UMA20-FEDERJA-074)
- Novartis Pharmaceuticals (LCZ696-2017)
- Consejería de Salud y Familias, Junta de Andalucía
- European Regional Development Fund
This publication has 44 references indexed in Scilit:
- Looking into the Kinetics of NT-proBNP and sST2 Changes in Patients with Heart Failure Treated with Sacubitril/Valsartan: A Hint to Different Therapeutic PathwaysDrugs in R&D, 2023
- Universal definition and classification of heart failure: a report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart FailureEuropean Journal of Heart Failure, 2021
- Circulating Levels and Prognostic Value of Soluble ST2 in Heart Failure are Less Influenced by Age than N-Terminal Pro-B-Type Natriuretic Peptide and High-Sensitivity Troponin TEuropean Journal of Heart Failure, 2020
- Association of Change in N-Terminal Pro–B-Type Natriuretic Peptide Following Initiation of Sacubitril-Valsartan Treatment With Cardiac Structure and Function in Patients With Heart Failure With Reduced Ejection FractionJAMA, 2019
- Effect of Sacubitril-Valsartan vs Enalapril on Aortic Stiffness in Patients With Heart Failure and Reduced Ejection FractionJAMA, 2019
- Biomarkers in heart failure: the past, current and futureHeart Failure Reviews, 2019
- Barcelona Bio-Hf Calculator Version 2.0: Incorporation of Angiotensin Ii Receptor Blocker Neprilysin Inhibitor (Arni) and Risk for Heart Failure HospitalizationEuropean Journal of Heart Failure, 2017
- LCZ696, An Angiotensin Receptor–Neprilysin Inhibitor, Improves Cardiac Function with the Attenuation of Fibrosis in Heart Failure with Reduced Ejection Fraction in Streptozotocin-Induced Diabetic MiceEuropean Journal of Heart Failure, 2016
- ST2 Testing for Chronic Heart Failure Therapy Monitoring: The International ST2 Consensus PanelThe American Journal of Cardiology, 2015
- The pathophysiology of heart failureCardiovascular Pathology, 2012